Physician profile
Travis John Morrell
NPI 1003130725
$539.05
in general payments reported to CMS, 2019-2025
12 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.38 · 2023: $128 · 2024: $164 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $526.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $130.31 | 2024-2025 | |
| Abbvie INC. | $91.21 | 2023-2025 | |
| Ucb, INC. | $68.96 | 2023-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $48.58 | 2022-2025 | Simponi, Stelara, Remicade |
| Biofrontera INC. | $38.97 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Amgen INC. | $28.00 | 2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $24.98 | 2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $23.96 | 2025 | Libtayo |
| Organogenesis INC. | $23.31 | 2024 | |
| Organon LLC | $22.75 | 2025 | Vtama |
| Kyowa Kirin, INC. | $21.49 | 2025 | |
| Sun Pharmaceutical Industries INC. | $16.53 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Morrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.